Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $178.1 million.

  • Zevra Therapeutics' Liabilities and Shareholders Equity rose 41.02% to $270.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $877.2 million, marking a year-over-year increase of 33.00%. This contributed to the annual value of $178.1 million for FY2024, which is 3.37% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Liabilities and Shareholders Equity of $178.1 million as of FY2024, which was up 3.37% from $172.3 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Liabilities and Shareholders Equity ranged from a high of $178.1 million in FY2024 and a low of $11.2 million during FY2020.
  • In the last 3 years, Zevra Therapeutics' Liabilities and Shareholders Equity had a median value of $172.3 million in 2023 and averaged $155.3 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Liabilities and Shareholders Equity soared by 1,086.02% in 2021, and later decreased by 13.24% in 2022.
  • Zevra Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $11.2 million in 2020, then surged by 1,086.02% to $132.9 million in 2021, then decreased by 13.24% to $115.3 million in 2022, then surged by 49.41% to $172.3 million in 2023, then rose by 3.37% to $178.1 million in 2024.